Diethylstilbestrol glutamate as a potential substrate for ADEPT

Area of Science:

• Oncology
• Medicinal Chemistry
• Biochemistry

Background:

• Diethylstilbestrol (DES) has limitations for prostate cancer treatment due to toxicity, poor water solubility, and chemical instability.
• Antibody-directed enzyme prodrug therapy (ADEPT) is a strategy that requires specific prodrug substrates.

Purpose of the Study:

• To investigate if diethylstilbestrol (DES) can serve as a prodrug substrate for antibody-directed enzyme prodrug therapy (ADEPT).
• To synthesize and characterize a novel DES-glutamate conjugate for potential ADEPT application.

Main Methods:

• Synthesis of DES-glutamate conjugate via activation of a glutamate ester and subsequent reaction with DES.
• Incubation of the DES-glutamate conjugate with carboxypeptidase G2 (CPG2) to assess enzymatic cleavage.
• High-performance liquid chromatography (HPLC) analysis to monitor the reaction progress and product formation.

Main Results:

• A water-soluble DES-glutamate conjugate was successfully synthesized.
• Incubation with carboxypeptidase G2 (CPG2) resulted in carbamate cleavage, releasing DES.
• Enzymatic activity of CPG2 was confirmed as necessary for the rapid cleavage of the glutamate moiety.

Conclusions:

• The synthesized DES-glutamate conjugate is a potential prodrug for ADEPT.
• Further investigation into the enzymatic kinetics of DES-glutamate cleavage by CPG2 is warranted.
• This study provides preliminary evidence for exploring ADEPT strategies with DES for prostate cancer treatment.